Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover

BACKGROUND: The Ovarian Protection Trial In Premenopausal Breast Cancer Patients “OPTION” trial (NCT00427245) was a prospective, multicenter, randomised, open label study evaluating the frequency of primary ovarian insufficiency (POI) at 12 months in women randomised to 6–8 cycles of (neo)adjuvant c...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilson, Caroline, Gossiel, Fatma, Leonard, Robert, Anderson, Richard A, Adamson, Douglas J A, Thomas, Geraldine, Coleman, Robert E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782022/
https://www.ncbi.nlm.nih.gov/pubmed/26998426
http://dx.doi.org/10.1016/j.jbo.2016.02.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4782022/
https://www.ncbi.nlm.nih.gov/pubmed/26998426
http://dx.doi.org/10.1016/j.jbo.2016.02.003

Ejemplares similares